Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How many blood eosinophil measurements are needed to identify COPD patients eligible for biologic therapy? A multi-source decision analysis simulation.

European journal of internal medicine·2026
Same author

Comparison of Three Devices Preventing Skin Damage During Facial Mask Ventilation in Acute Respiratory Failure: Multicenter Randomized Controlled Trial Protocol (3PROSNIVtrial).

Pulmonary therapy·2026
Same author

Beyond Triple Therapy: Anti-Type 2 Biologic Therapies for Eosinophilic COPD and Respiratory Comorbidities - a Review of Clinical Evidence.

Current allergy and asthma reports·2026
Same author

Impact of Dupilumab on Small Airway Disease in Severe Asthma: A 12-Month Retrospective Real-World Study.

Advances in respiratory medicine·2026
Same author

High-Frequency Chest Wall Oscillation in Critical Care: A Systematic Review.

Respiration; international review of thoracic diseases·2026
Same author

<i>Cedecea lapagei</i> pneumonia: the first reported case in Italy and literature review.

Le infezioni in medicina·2026
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

[Drug-induced diffuse infiltrative pneumopathies].

Raffaele Scala1, Mario Naldi, Cesario Ciccotosto

  • 1UO Pneumologia, UTSIR e Endoscopia Toracica, Ospedale S. Donato, AUSL 8 Arezzo. raffaele_scala@hotmail.com

Recenti Progressi in Medicina
|June 28, 2008
PubMed
Summary
This summary is machine-generated.

Drug-induced diffuse infiltrative pneumopathies (DIP) are a growing concern, with over 350 implicated drugs. A multidisciplinary approach is crucial for accurate diagnosis and management of these drug-induced lung injuries.

More Related Videos

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Related Experiment Videos

Last Updated: Jul 4, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Area of Science:

  • Pulmonology
  • Toxicology
  • Radiology

Context:

  • Drug-induced diffuse infiltrative pneumopathies (DIP) are a significant cause of respiratory illness.
  • Over 350 drugs are known to cause lung toxicity, with new agents continually identified.
  • Accurate diagnosis of drug-induced lung injury requires collaboration among pulmonologists, radiologists, and pathologists.

Purpose:

  • To review the clinical, radiological, pathological, and therapeutic aspects of drugs most likely to cause DIP.
  • To highlight the importance of a multidisciplinary approach in managing drug-induced lung diseases.

Summary:

  • This review details the characteristics of drugs commonly causing DIP.
  • It emphasizes the integrated diagnostic process involving clinical presentation, imaging, and histopathology.
  • Therapeutic strategies for drug-induced lung injury are also discussed.

Impact:

  • Enhances understanding of drug-induced lung diseases for clinicians.
  • Promotes a collaborative diagnostic and management strategy.
  • Aims to improve patient outcomes in drug-induced pneumonitis.